Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FGJU2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,485
Award facts
- Contract value 100% obligated
- $10,484.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,484.64 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL auto-injector vials. This firm fixed-price delivery order, issued on January 28, 2026, with an ultimate completion date of February 19, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The work will be performed at the contractor's Park Ridge, Illinois facility.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to ensure consistent pharmaceutical supply to Department of Defense military healthcare facilities worldwide. The underlying PPV-G GEN V contract, awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period and three optional 30-month renewal periods. DMS Pharmaceutical Group serves as one of multiple regional prime vendor contractors under this vehicle, positioned to supply a broad range of branded and generic prescription medications, biologics, vaccines, and medical consumables to support DoD healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FGJU2?
SPE2DR26FGJU2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FGJU2 worth?
The government has obligated $10,485 on SPE2DR26FGJU2.
Is contract SPE2DR26FGJU2 an order under another contract?
Yes. SPE2DR26FGJU2 is a delivery order under SPE2DR25D9832, an indefinite delivery contract.
Was contract SPE2DR26FGJU2 competed?
The extent of competition for SPE2DR26FGJU2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award